Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid ...
Sep 13, 2024
0
0